The results showed that adding semaglutide to SGLT2 inhibitor therapy significantly improves glycemic control and reduces body weight in patients with inadequately controlled T2DM and is generally well tolerated [119]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.